Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TOP2A-normal breast cancer: DBCG 07-READ, an open-label, phase III, randomized trial. J Clin Oncol 2017; 35: 2639-2646.

Published: 5th January 2018

Authors: Ejlertsen B, Tuxen MK, Jakobsen EH, Jensen M-B, Knoop AS, Højris I et al.

Conclusion

There was no difference between the two regimens in this study that included 2012 women, and thus no evidence to support the use of adjuvant anthracyclines in this particular group.

Pubmed Link

Your comments

0 Comments